Ypsomed

Ypsomed is a medical technology company that specialises in drug delivery devices for self-injection, under the Ypsomed Delivery Systems brand, and products for diabetic patients, under the mylife Diabetescare brand. Ypsomed develops a range of autoinjector, pen injector and wearable injector platforms.

Headquarters
Ypsomed AG
Brunnmattstrasse 6
CH-3401 Burgdorf
Switzerland

Phone / Contact

T: +41 34 424 41 11
F: +41 34 424 41 22
E: [email protected]

Connect

Ypsomed is an independent developer and manufacturer of autoinjector and pen injector systems for self-administration of injectable drugs. The company provides customisable product platforms for autoinjectors for prefilled syringes in 1 mL and 2.25 mL format, disposable pens for 3 mL and 1.5 mL cartridges, reusable pens that include automated injection mechanisms, and injection devices for drugs in dual-chamber cartridges, such as lyophilised drugs. Click-on needles and infusion sets complement the company’s self-injection systems product portfolio.

The company’s device offering includes:

YpsoMate, VarioJect and LyoTwist autoinjectors
ServoPen, YpsoPen, UnoPen and FixPen pen injectors
YpsoDose wearable injector
SmartPilot connected add-on.

Ypsomed has more than 35 years of experience working with pharma and biotech companies in the parenterals sector. The company is ISO13485 certified and all processes are run according to design control and cGMP guidelines. Ypsomed operates the mylife Diabetescare brand for marketing to patients and pharmacies, and the Ypsomed Delivery Systems brand for business-to-business operations. Ypsomed Group employs around 1500 people.

Articles by Ypsomed

Thomas Fontanellaz

SUBCUTANEOUS DRUG DELIVERY: ADAPTING TO HIGH-VISCOSITY, LARGE-VOLUME DEMANDS

Thomas Fontanellaz, Reto Jost and Andreas Schneider discuss how Ypsomed is addressing the growing need for subcutaneous injections that accommodate higher volumes and viscosities, with innovative self-injection devices designed to enhance patient comfort and adherence.

INDUSTRIALISATION

YPSOMED’S PLATFORM PRODUCT TRANSFORMATION AND APPROACH TO STRATEGIC PARTNER NETWORKING FOR SELF-INJECTION DEVICES

Ian Thompson describes how Ypsomed has transformed the market for platform-based self-injection devices and extended the concept of platform products beyond the core device by developing working practices with strategic networking partners, helping pharma companies and patients to source safe, reliable and easy-to-use drug-device combination products.

Dr Stefanie Seiler

DIGITAL SELF-CARE – SOLVING PATIENT CHALLENGES WHILE DELIVERING BUSINESS INSIGHTS TO PHARMA

Stefanie Seiler and Ventsislav Dobrev discuss self-care challenges for patients and highlight how Ypsomed Digital Health’s solutions can solve them while also delivering meaningful business insights for pharmaceutical companies.

INTERVIEW: THE BENEFITS OF BEING AN EARLY ADOPTER OF SUSTAINABILITY PRINCIPLES

Reto Jost and Gabriel Kalbermatter talk exclusively with ONdrugDelivery's Guy Furness, discussing the progress Ypsomed has made in advancing its sustainability agenda, particularly the implementation of its ecodesign guideline, the benefits of being an early adopter of sustainability principles, how YpsoMate 5.5 mL has been designed from the ground up with sustainability in mind and where sustainability considerations currently fit into the wider pharma industry.

HOW DIABESITY IS SHAPING THE WORLD OF SELF-INJECTION DEVICES

Ian Thompson takes us through the recent history of diabetes and obesity therapeutics, the innovative peptide hormone molecules that have reached the market over the past decades and the equally innovative devices developed to deliver them. He addresses the growing challenge of diabesity, and shows that diabetes and obesity will continue to influence self-injection device development substantially.

AUTOINJECTORS FOR LARGE-VOLUME SUBCUTANEOUS DRUG DELIVERY

Ian Thompson provides a summary of a recent literature review on subcutaneous administration with dose volumes greater than 1.0 mL, which examines how previous studies have addressed the limitations and considerations for designing and developing large-volume autoinjectors.

Christian Esser Wiesemann

YPSODOSE – THE CLINIC-READY 10 ML PATCH INJECTOR

Christian Esser Wiesemann provides the latest insights into the prefilled and pre-assembled YpsoDose patch injector, which is now available for clinical trials.

Ventsislav Dobrev

Real-World Evidence in the Age of Digital Health – Unlocking Value for Pharmaceutical Companies

Ventsislav Dobrev, Philippe Müller and Rafael Weiler explore how real-world evidence in the age of digital health can help unlock value for pharmaceutical companies.

Dr Andreas Schneider

HOW PATIENT & TREATMENT FACTORS SHAPE SUBCUTANEOUS DOSING PREFERENCES

Andreas Schneider highlights the importance of understanding the drivers of dosing preferences when it comes to choosing the right injection device for patients. Specifically, the research summarised here studies whether and how patient characteristics and treatment attributes influence the decision to use prefilled handheld autoinjectors or large-volume wearable injectors.

Florian Krummenacher

DESIGNING EFFECTIVE AND ENGAGING DIGITAL SOLUTIONS TO DRIVE ADHERENCE

Florian Krummenacher and Philippe Müller discuss the effectiveness of combining connected injection devices with digital solutions to drive therapy outcomes.

Sebastian Gerner

YPSOMED’S TWO-STEP APPROACH TO ACHIEVING NET ZERO

Sebastien Gerner discusses Ypsomed’s approach to achieving its net zero objectives, both looking back at Step One of the company’s approach and outlining the upcoming Step Two.

THE NEW YPSOMATE™ 5.5 – TAKING HANDHELD SELF-INJECTION BEYOND VOLUMES OF 2 ML

Reto Jost introduces YpsoMate 5.5, the staked-needle-syringe-based, two-step autoinjector for injection volumes in the 2.0–5.5 mL range, and discusses the drivers of the demand for high-volume, high-rate subcutaneous drug delivery using handheld autoinjectors.

WEARABILITY AND USABILITY OF THE YPSODOSE 10 mL PATCH INJECTOR

Jakob Lange discusses the results of a recently published study into the usability and wearability of the YpsoDose 10 mL patch injector, providing a summary of the insights acquired during the study.

Dr Andreas Schneider

PAVING THE WAY TO INTEGRATED DEVICE-DIGITAL SOLUTIONS

Andreas Schneider and Philippe Müller discuss the potential benefits and challenges of implementing connected device-digital solutions within the healthcare sector to improve the treatment of chronic conditions.

Philippe Müller

YPSOMATE ON – GO FOR SIMPLY CONNECTED

Philippe Müller and Silas Mächler discuss the benefits of integrated digital therapy management systems and the role of YpsoMate On – the newest addition to Ypsomed’s connected device portfolio, and the world’s first prefilled autoinjector with integrated connectivity that automatically logs injections on the user’s therapy management app.

YPSODOSE – SIMPLIFYING LARGE-VOLUME PATCH INJECTIONS

Ian Thompson provides the latest insights into the YpsoDose prefilled and pre-assembled patch injector as it moves into the industrialisation phase for clinical trials.

Dr Andreas Schneider

TOWARDS USER-CENTRIC SPECIFICATION OF AUTOINJECTOR TECHNICAL ATTRIBUTES: INSIGHTS FROM EMPIRICAL WORK

Andreas Schneider discusses an empirical study into both users’ ability to remove the cap from an autoinjector and the difficulty those patients perceived in doing so. The study builds a quantitative model relating the empirical data to patient perception.

Dr Andreas Schneider

HOW LONG CAN YOU HOLD THE DEVICE AGAINST THE SKIN? INSIGHTS FROM AN EMPIRICAL STUDY USING HAND-HELD AUTOINJECTORS

Andreas Schneider summarises recent empirical work investigating the ability of users of hand-held devices to complete longer injection times effectively. The study provides insights into the effects of injection duration on the force exerted by the user to hold the device against the injection site.

Sebastian Gerner

PAVING THE WAY TO ZERO CARBON EMISSION COMBINATION PRODUCTS: THE YPSOMATE ZERO CASE STUDY

Sebastian Gerner and Andreas Schneider discuss the relationship between the medical device industry and the global issue of plastic waste. The authors introduce YpsoMate Zero as a case study, Ypsomed’s net-zero carbon emission prefilled autoinjector.

SIMPLIFYING LARGE-VOLUME PATCH INJECTION FOR PHARMA AND PATIENTS

Reto Jost provides an update on the YpsoDose platform and its importance as the driver for the business unit’s new patch injector franchise.

Dr Andreas Schneider

HOW USERS DISTINGUISH BETWEEN SELF-INJECTION DEVICE PLATFORM VARIANTS

Andreas Schneider highlights how the ever-increasing interest in device platforms raises concerns around the broad availability of lookalike autoinjectors that may result in inappropriate medication usage. He summarises a recent empirical study¹ providing insights into which device attributes drive device distinguishability.

Orfeo Niedermann

SUCCESS FACTORS FOR THE YPSOMATE FAMILY OF AUTOINJECTORS

Orfeo Niedermann looks at the key factors behind the growth and continued success of the YpsoMate family of two-step autoinjectors. He also introduces YpsoMate Design, which enables freeform outer shell design around the proven YpsoMate mechanism and manufacturing lines.

LARGE-VOLUME PATCH-INJECTION VIA YPSODOSE: SIMPLER FOR PHARMA COMPANIES & PATIENTS

Ian Thompson updates us on the company’s prefilled large-volume patch injector platform, YpsoDose, which simplifies the approach to wearable patch injectors for both pharma companies and patients.

Dr Andreas Schneider

I SPY WITH MY LITTLE EYE: EYE TRACKING DRIVES PATIENT-CENTRED DEVELOPMENT OF CONNECTED SYSTEMS

The development of connected self-injection systems is driving industry to rethink its current approaches to patient-centred new product development. Andreas Schneider summarises a recent field study that used eye tracking for the formative usability testing of SmartPilot for YpsoMate.

Top